Kura Oncology spins off Caspian Therapeutics to test leukemia drug mechanism in diabetes

The short version

• Caspian Therapeutics launched with $50 million in funding to develop menin inhibitors for diabetes and cardiometabolic diseases.[STAT]
• The venture emerged after Kura Oncology researchers found that targeting menin controlled blood sugar in animal leukemia studies.[STAT]
• BVF Partners led the financing round alongside Eli Lilly and Kura executives, while Kura maintains about 50% ownership.[STAT]
• The capital is intended to advance a lead small-molecule drug into early clinical trials, though human efficacy remains unproven.[STAT]

Key facts

• Caspian Therapeutics launched with $50 million in financing to create menin inhibitors for diabetes and cardiometabolic disorders.[STAT]
• Kura Oncology researchers discovered that inhibiting the menin protein regulated blood sugar in animal models during leukemia research.[STAT]
• BVF Partners led the funding round, which included investments from Eli Lilly and Kura leadership.[STAT]
• Kura Oncology will keep approximately 50% ownership of the new spinoff.[STAT]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that ideaSTAT metered